Posted by Michael Wonder on 31 Aug 2017
FDA expands use of Teva’s Austedo in Parkinson’s
31 August 2017 - Teva’s Austedo is now the first and only therapy approved in the US to treat both tardive dyskinesia and chorea associated with Huntington’s disease.
US regulators have widened the scope of the drug - initially approved for chorea associated with the disease in April 2017 - to include treatment of tardive dyskinesia in adults with the condition.
Tardive dyskinesia is a debilitating movement disorder characterised by repetitive and uncontrollable movements of the tongue, lips, face, trunk and extremities, affecting around 500,000 people in the US.
